Intera3000肝动脉灌注泵
Search documents
波士顿科学携13款微创创新产品亮相进博优品会 赋能健康中国建设
Jing Ji Guan Cha Wang· 2025-12-19 14:55
科普赋能:让医疗科技触手可及 随着我国老年人口突破3 亿大关,老龄化带来的健康挑战与社会负担日益凸显。围绕人口老龄化加速背 景下的银龄健康需求,波士顿科学带来了多款与中国老龄患者需求紧密契合的微创介入解决方案,包括 用于房颤治疗的明星产品FARAWAVE NAV一次性使用磁定位心脏脉冲电场消融导管;房颤患者卒中预 防"利器"新一代WATCHMAN FLX Pro左心耳封堵器;用于心脏节律管理的S-ICD皮下植入式除颤器和 起搏器、除颤器;治疗良性前列腺增生的Rezūm前列腺热蒸汽治疗系列产品,以及神经调控领域改善帕 金森病症状的Vercise Genus植入式脑深部神经刺激(DBS)系列产品。 波士顿科学还带来多项突破性疗法,为患者带来更多元的治疗选择:可预防经导管主动脉瓣置换术 (TAVR)中发生脑卒中的SENTINEL抗栓塞脑保护装置 ;用于颈动脉狭窄创新术式经颈动脉血管重建 术(TCAR)的ENROUTE经颈动脉逆流血栓保护装置 ;用于原发性肝癌治疗的TheraSphere Y90钇 [90Y]玻璃微球系统;美国FDA唯一批准的肝动脉灌注(HAI)疗法产品Intera3000肝动脉灌注泵* ,为 结直肠 ...
进博会首日“最卷展区”创新药械扎堆亮相,多个“全勤生”再赴约
Xin Jing Bao· 2025-11-06 03:32
Core Insights - The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, showcasing innovations in the medical device and pharmaceutical sectors under the theme "Healthy China, Beautiful Life" [1] - The medical device and pharmaceutical health exhibition area, known for its high competition, featured global leaders in medical technology and pharmaceuticals, including the top ten medical device companies and 11 Fortune 500 pharmaceutical firms [1] Company Highlights - **Roche**: Displayed over 40 products, including new treatments for Alzheimer's, Parkinson's, and lupus nephritis, with the anti-CD20 monoclonal antibody, Gazyva, and the Port Delivery System (PDS) for eye diseases being key highlights [2][4][5] - **Siemens**: Focused on high-incidence cancers, showcasing advanced technologies like the ARTIS icono ceiling Xpand and the Biograph Vision Quadra PET/CT, aimed at improving diagnostic precision and treatment outcomes [6][7] - **Novartis**: Presented nearly 20 innovative products, including the oral complement factor B inhibitor, Iptacopan, and the radioligand therapy drug, Pluvicto, which received approval for prostate cancer indications [10][12] - **Fosun Pharma**: Introduced the Marie upright particle therapy system, a revolutionary cancer treatment technology, along with advanced non-invasive treatment systems for neurological conditions [12][14] - **Boston Scientific**: Showcased over 80 products in the minimally invasive intervention field, including the Orbera365 gastric balloon system and the Intera3000 hepatic artery infusion pump, with several products making their debut [15][17] - **Novo Nordisk**: Highlighted advancements in diabetes and obesity treatments, including the oral GLP-1 receptor agonist, Rybelsus, and the weekly insulin formulation, IcoSema, which have significantly improved patient convenience [18][20]
多款“全球首秀”药械亮相进博会,聚焦老龄化、减重庞大需求
Di Yi Cai Jing· 2025-11-05 11:19
Core Insights - The eighth China International Import Expo (CIIE) showcased several innovative medical devices and healthcare products, attracting significant attention from global trade delegations [1][2] Group 1: Medical Devices - Boston Scientific presented the ENROUTE Transcarotid Artery Revascularization (TCAR) device, the first and only approved device for TCAR procedures, aimed at reducing intraoperative risks associated with carotid artery stenosis [1] - Another product from Boston Scientific, the FARAWAVE NAV catheter, utilizes non-thermal electric fields for cardiac tissue ablation and has treated approximately 500,000 patients globally [1] - Medtronic introduced the Inceptiv closed-loop rechargeable spinal nerve stimulation system, designed to improve the quality of life for patients with chronic pain through weak electrical stimulation [4] - BD Medical showcased the M.R.I™ 4F Slim Implantable Port, the thinnest catheter in its category, designed for the Chinese population, which significantly reduces thrombosis rates by 40% [4] - The Venclose™ catheter, designed for treating lower limb varicose veins, features a flexible setup that minimizes patient trauma [5] Group 2: Innovative Treatments - Fosun Pharma presented the Exablate Neuro system, a high-intensity focused ultrasound (HIFU) device combined with MRI for treating drug-resistant essential tremors and Parkinson's disease [6] - Eli Lilly introduced innovative drugs targeting aging and obesity, including donanemab for Alzheimer's disease, which has shown to delay disease progression by approximately 30% in clinical trials [6]